Ucb Pharma S.A.

52 patents currently held · Updated Nov 14, 2026

101 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

Ending by 2030

Dec 2026

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 25, 2027
The maintenance fee for Three-Dimensional Medical Image Analysis Method and System for Identification of Vertebral Fractures (US 11,710,233) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
1 fee due Feb 18, 2027
The maintenance fee for Bacterial Host Strain (US 9,109,216) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
1 fee due May 21, 2027
The maintenance fee for Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides (US 11,820,746) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
1 fee due Jun 26, 2027
The maintenance fee for Anti-Sclerostin Antibodies and Their Use to Treat Bone Disorders as Part of a Regimen (US 11,851,483) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
1 fee due Aug 13, 2027
The maintenance fee for Treatment for bone diseases (US 11,896,667) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
1 fee due Sep 26, 2027
The maintenance fee for Pyridinyl and pyrazinyl-(asa)indolsulfonamides (US 11,939,319) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
2 fees due Oct 12 to 19, 2027 · next Oct 12
1 fee due Nov 7, 2027
The maintenance fee for Substituted alkoxypyridinyl indolsulfonamides (US 11,976,056) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

5 terms have ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,670,621	Transdermal Administration of (R)-3,3-Diphenylpropylamin-MONOESTERS In force Term ends Dec 17, 2026 · High confidence	In force	Term ends Dec 17, 2026	High confidence
US 8,394,822	Thieno-pyridine derivatives as MEK inhibitors In force Term ends Jan 30, 2027 · From the USPTO record	In force	Term ends Jan 30, 2027	From the USPTO record
US 8,604,051	Thieno-pyridine derivatives as MEK inhibitors In force Term ends Jan 30, 2027 · From the USPTO record	In force	Term ends Jan 30, 2027	From the USPTO record
US 8,742,140	Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof In force Ends no later than Jun 6, 2027 · From the USPTO record	In force	Ends no later than Jun 6, 2027	From the USPTO record
US 9,309,215	Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof In force Ends no later than Jun 6, 2027 · From the USPTO record	In force	Ends no later than Jun 6, 2027	From the USPTO record
US 7,807,715	Pharmaceutical compositions comprising fesoterodine In force Term ends Jun 7, 2027 · From the USPTO record	In force	Term ends Jun 7, 2027	From the USPTO record
US 9,364,541	Pharmaceutical compositions comprising Fesoterodine In force Ends no later than Jun 7, 2027 · From the USPTO record	In force	Ends no later than Jun 7, 2027	From the USPTO record
US 9,095,557	Anticonvulsant combination therapy In force Ends no later than Jun 15, 2027 · From the USPTO record	In force	Ends no later than Jun 15, 2027	From the USPTO record
US 9,446,011	Anticonvulsant combination therapy In force Term ends Jun 15, 2027 · From the USPTO record	In force	Term ends Jun 15, 2027	From the USPTO record
US 7,982,058	Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof In force Term ends Aug 2, 2027 · From the USPTO record	In force	Term ends Aug 2, 2027	From the USPTO record

10 of 52 patents shown.

Pro members see all 52.

Pro members: see all 52 patents

Also on record, not counted in the 52: 101 patents in force now held by others · 202 lapsed for an unpaid fee · 76 ended at full term · 3 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 7 abandoned · 62 no status recorded

List them